ClinicalTrials.gg
TerminatedNCT04067492Updated Jul 25, 2022Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

A Phase 2 interventional study of RPH - 104 and Voltaren® in Gout Attack, sponsored by R-Pharm. Terminated at 11 sites in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-25.

Sponsored by R-Pharm · Phase 2, Interventional, and Treatment

Why this study was terminated
In view of the continuing insufficient patient recruitment in the study due to the difficult epidemiological situation and the need for rational allocation of company resources, as well as based on the results of the interim analysis.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2018, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary goal of the study was to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.

Read the detailed description

The study consisted of two periods:

Period 1. In Study Period 1, eligible patients were enrolled in a group of 22 patients and randomized to receive either RPH-104 4 mg or Voltaren® (diclofenac) in the 15:7 ratio (15 RPH-104: 7 Voltaren® (diclofenac)). In order to prevent damage to the gastric and duodenal mucosa caused by Voltaren® (diclofenac), all patients receiving Voltaren® (diclofenac) had to simultaneously take Ortanol® (omeprazole) 20 mg, orally (1 capsule) daily before breakfast throughout the course of Voltaren® (diclofenac) treatment

Period 2. Upon completion of the enrollment of 22 patients, Study Period 2 started. In Period 2, newly enrolled patients were randomly assigned to one of 5 treatment groups: RPH-104 20 mg, 40 mg, 80 mg and 160 mg and active control (Voltaren® (diclofenac)). It was planned to include 14 patients in the RPH-104 groups in Period 2, and 7 patients in the Voltaren® (diclofenac) group.

The enrollment of patients in Period 1 and Period 2 was sequential. There was no pause between the enrollment of patients in Period 1 and Period 2. The study design included screening (24 hours), 11 visits to the study site, and a phone call at the end of the 60-day follow-up period.

Total number of patients which were planned to be enrolled for the study: 85 (15 patients in the group of treatment with RPH-104 4 mg and 14 patients in the each of the other treatment groups). Due to the low patient recruitment rate in the study and the negative impact of the COVID-19 pandemic on the recruitment, at the decision of the sponsor, an interim analysis of the data of 47 patients included in the study as of November 2020 was carried out in order to assess the feasibility of continuing recruitment and further conducting the study.

Patients who did not tolerate pain were allowed to receive a rescue medication, triamcinolone acetonide 40 mg intramuscularly, to intensify therapy 2 hours after the test product was administered. If the attack recurred after the use of the rescue medication, treatment was carried out in accordance with the standard practice of the hospital.

The primary efficacy endpoints were evaluated 72 hours after the end of administration of the test drug. The secondary efficacy endpoints were evaluated for 45 days of the treatment period and follow-up. The safety parameters were evaluated for 60 days of the treatment period and follow-up. Total duration of the study for a volunteer was not more than 70 days.

02

Conditions studied

  • Gout Attack

Keywords

  • hyperuricemia
  • acute arthritis
  • gouty arthritis
  • gout
03

In context

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

This study's enrollment of 47 is below the median of 68 across 193 interventional studies indexed under Hyperuricemia.

Browse Hyperuricemia studies →

Lead sponsor

R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. The subject has given his / her to participate in this study; the Informed Consent Form has been signed both by the patient and the Investigator;
    1. Established diagnosis of gout according to Gout Classification Criteria established by the American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) in 2015;
    1. Pain in at least one joint at the screening and immediately prior to initiation of therapy with the study drugs, with intensity 50 mm to 100 mm according to the Visual Analogue Scale (VAS);
    1. Development of acute gout attack within 120 hours (5 days) prior to the randomization date;
    1. History of 1 or more acute gout attacks prior to the Screening Visit;
  • 6.The patients receiving uric acid-lowering drugs should continue receiving these drugs at a constant dose for at least 4 weeks prior to enrolment to the study and throughout the entire study period; the patients not receiving uric acid-lowering drugs may start receiving this treatment after the end of the study;
    1. ≤40 kg/m2;
    1. interval ≤450 msec for male subjects and ≤470 msec for females on at the screening;
    1. For women of : negative result of the serum pregnancy test performed at the screening;
    1. The consent of a woman of child-bearing potential, as well as of a man who has female partners of child-bearing potential, to abstain from sexual intercourses or to use effective methods throughout the entire study period and for 60 days after RPH-104 administration (if the patient received RPH-104);
    1. The patient is able to fulfil the requirements of the Study Protocol as judged by the Investigator

Exclusion criteria

Exclusion Criteria:

    1. The patient received therapy with ibuprofen in a dose of up to 400 mg inclusive within 4 hours or >400 mg within 8 hours prior to randomization.
    1. The patient received therapy with diclofenac in a dose of up to 50 mg inclusive within 8 hours or >50 mg within 24 hours prior to randomization.
    1. The patient received any other non-steroidal anti-inflammatory drug (NSAID) within 24 hours prior to the randomization;
  • 4.The patient received opioids within 48 hours prior to the randomization;
    1. The patient received metamizole or metamizole-containing drugs within 12 hours prior to the randomization;
    1. The patient received any drug with analgesic activity (including paracetamol) within 6 hours prior to the randomization;
    1. The patient received a long-acting NSAID (half-life ≥24 hours) within 5 half-life periods or 1 month prior to the randomization whichever is longer;
    1. The patient received extended-release naproxen, meloxicam, nabumetone, celecoxib, etoricoxib or indomethacin within 5 days prior to the randomization;
  • 9 . The patient received (including their intra-articular administration and inhalations) within 4 weeks prior to the randomization;
    1. The patient received colchicine within 7 days prior to the randomization;
    1. Intolerance or for NSAID use;
    1. Contraindications for the use of Ortanol® capsules 20 mg;
    1. Chronic heart failure functional class II-IV (classification of );
    1. A history of or current ventricular arrhythmias or clinically significant atrial tachyarrhythmias;
    1. Unstable angina or stable exercise-induced angina of functional class III or IV;
    1. Secondary gout, chemotherapy-induced gout, lead- or transplantation-induced gout;
    1. Rheumatoid arthritis, confirmed or suspected infectious septic arthritis or any other type of acute inflammatory arthritis;
    1. Clinically significant renal impairment determined based on (estimated using the Cockcroft-Gault equation) \<60 mL/min, or patients on hemodialysis;
    1. Blood coagulation disorders; history of gastrointestinal bleedings or perforation;
    1. Pregnant or breast-feeding women;
    1. Elective surgery or major surgical intervention (minor surgical procedures, such as catheter placement or bone marrow , are not exclusion criteria) within 14 days before the first dose of the medicinal product;
    1. Current or suspected -infection, , Virus antibodies (HCVAb), other acute or chronic bacterial, fungal or viral infections at the moment of subject's enrolment to the study;
    1. Presence of any risk factors for tuberculosis based on the results of assessment using Tuberculosis Risk Assessment Questionnaire at the screening or confirmed tuberculosis or any other infectious disease of the lungs or bronchi based on findings of the chest X-ray exam in two views performed within 3 months prior to the screening visit, or the need for using therapy with tuberculosis medications, such as isoniazid in the course of the study;
    1. Neutropenia, leukopenia, or thrombocytopenia determined based on the following laboratory parameters assessed during the screening:

      1. (ANC) \<1.5 x 10\^9/L;
      2. White blood cell count \<4.0 х 10\^9/L
      3. count \<150 х 10\^9/L;
    1. Immunization with within 3 months prior to the subject's enrolment to the study or planned vaccination within 60 days after the expected date of the first dose of the test drug;
    1. History of allergic reactions to biologicals, Voltaren® (diclofenac) or Ortanol® (omeprazole);
    1. Contraindications for subcutaneous, intramuscular, intravenous or intra-articular injections;
    1. History of (except for patients with localized in situ basal cell carcinoma of the skin or in situ cervical cancer, who can be enrolled to the study immediately after the therapy for this disease), unless it is in remission for ≥5 years, as well as patients who are being examined for cancer or patients with suspected malignancy;
    1. A condition or disease, which, in the Investigator's opinion, could put the patient's safety at risk or affect the test drug safety assessment;
    1. Any other conditions and diseases, such as uncontrolled diabetes mellitus, uncontrolled hypertension, congestive heart failure, exacerbation of peptic ulcer disease, clinically significant liver diseases, kidney diseases, uncontrolled thyroid dysfunction, unhealed wounds, ulcers or bone fractures, psychiatric disorders, uncontrolled epilepsy, drug dependence, which could prevent the patient from complying with this Study Protocol.
    1. The patient received biologicals or investigational medicinal products within 5 half-life periods of these drugs or 3 month prior to the randomization whichever is longer;
    1. Blood donation or blood loss of ≥400 mL within 8 weeks prior to the randomization.
    1. The patient was already randomized in this clinical study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    RPH - 4 mg

    Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.

    Drug: RPH - 104

  • Experimental
    RPH - 20 mg

    Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.

    Drug: RPH - 104

  • Experimental
    RPH - 40 mg

    Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.

    Drug: RPH - 104

  • Experimental
    RPH - 80 mg

    Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.

    Drug: RPH - 104

  • Experimental
    RPH - 160 mg

    Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)

    Drug: RPH - 104

  • Active comparator
    Voltaren® (diclofenac)

    Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)

    Drug: Voltaren®

Interventions

  • solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

  • Enteric-coated tablets, 25 mg and 50 mg

    Also known as: Diclofenac

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline

    Change in pain intensity in the assessed joint 72 hours after the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) in comparison to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

    Time frame: Baseline and Day 4 (72 hours after the initiation of treatment with the test drug)

Secondary outcomes

  1. Change in Pain Intensity in the Assessed Joint in 15, 30, 45 Minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 Hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 Following the Initiation of Treatment and Compared to Baseline

    Change in pain intensity in the assessed joint in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) and compared to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

    Time frame: Baseline and 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment

  2. Proportion of Patients Who Assessed the Response to Therapy With the Test Drug as "Excellent" or "Good"

    Proportion of patients who assessed the response to therapy with the test drug as "Excellent" or "Good" in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug. The patient's response to therapy was assessed in the form of frequency tables by assessment point and therapy group. The rates of the response were specified in the evaluation form as: "Excellent", "Good", "Fair", "Weak", "Poor" (where "excellent" represents the best possible response to treatment and "poor" indicates the worst treatment response).

    Time frame: 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment with the test drug

  3. Change in the Rate of Swelling of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

    Change in the rate of swelling of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. The rates of swelling were specified in the evaluation form as: "absence" = no swelling, "mild" = palpable swelling, "moderate" = visible swelling, "severe" = bulging outside the joint (where "severe" represented the worst possible degree of swelling and "absence" was the best outcome).

    Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug

  4. Change in the Rate of Tenderness of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

    Change in the rate of tenderness of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. Tenderness degrees: "absent" = no tenderness, "mild" = tenderness when touched, "moderate" = pain and flinching, "severe" = pain, flinching and withdrawal of the limb (where "severe" represents the worst possible degree of tenderness and "absent" is the best outcome).

    Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug

  5. Change in the Rate of Erythema of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

    Change in the rate of erythema of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline.The rates of "erythema" were specified as "absence", "presence", "impossible to evaluate".

    Time frame: Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug

  6. Change in the Rate of Movement Restrictions in the Specified Timeframes After Initiation of Treatment

    Change in the rate of movement restrictions in the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. For the assessment, the categorical scale consistent with the Form for evaluation (Investigator's Assessment) of the restriction of movements was used. The rates of movement restrictions (amplitude of movements) were specified in the evaluation form as "1 - Normal range", "2 - Slightly limited range", " 3 - Moderately limited range" ,"4 - Severely limited range" and "5 - Joint movement is impossible " (where higher score means worse outcome).

    Time frame: Baseline and in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug

  7. Time to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the Baseline

    Time to achieve the 50% decrease in pain intensity in the assessed joint relative to the baseline VAS level. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)). The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

    Time frame: Baseline and one of the pain intensity measurements in accordance with the schedule: 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment

  8. Time to Use of the Rescue Medication

    Time to use of the rescue medication was calculated as the time in hours from the date/time of administration (first dose) of the investigational product to the date/time of the first use of the rescue medication.

    Time frame: from the date/time of IP administration (first dose) to the date/time of the first use of the rescue medication, up to day 60

  9. Proportion of Patients Who Received a Rescue Therapy Agent

    The proportion of patients who received the rescue medication within 72 hours of starting the investigational product therapy

    Time frame: 72 hours after the initiation of treatment with the test drug

  10. Proportion of Patients Who Received a Rescue Therapy Agent

    The proportion of patients who received the rescue medication over the entire treatment period

    Time frame: up to day 60

  11. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Disability Index

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. (The result for each of the 8 categories ("Dressing and Grooming", "Arising", "Eating", "Walking", "Hygiene", "Reach", "Grip", "Activities") of the HAQ questionnaire was calculated as the maximum score of responses (on an ordinal scale from 0 (best) to 3 (worst): without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3)) to questions included in this category. If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2". The sum of points for the evaluated categories was calculated and divided by the number of categories, which gives a disability index in the range of 0 to 3.)

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

  12. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Arising

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

  13. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Eating

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

  14. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Walking

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

  15. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Hygiene

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

  16. Changes in the Health Assessment Questionnaire (HAQ) Parameters: Grip

    Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

    Time frame: Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug

Other outcomes

  1. Pharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration

    Including area under the plasma concentration-time curve over the dosing interval (AUC0-tau)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  2. Pharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration

    Including Area under the active substance concentration-time curve from zero (before drug administration) to infinity (AUC0-∞)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  3. Pharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration

    Including Maximum concentration of the active substance (Cmax)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  4. Pharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration

    Including elimination constant (Kel)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  5. Pharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration

    Including Time to reach maximum concentration of the active substance (tmax)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  6. Pharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration

    Including terminal half-life (T 1/2)

    Time frame: Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)

  7. Change in the Serum Rate of High-sensitive CRP (Hs-CRP) in Specified Timeframes

    Change in the serum rate of high-sensitive CRP (hs-CRP) in 24, 72 hours, on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug compared to baseline

    Time frame: Baseline and in 24, 72 hours, on Days 5, 6, 15, 29 and 45 after the initiation of treatment with the test drug

  8. Change in the Rate of Serum Amyloid Protein A in the Specified Timeframes

    Change in the rate of serum amyloid protein A in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  9. Change in the Serum Rates of Cytokines: IL-1α

    Change in the serum rates of IL-1α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  10. Change in the Serum Rates of Cytokines: IL-1β

    Change in the serum rates of IL-1β in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  11. Change in the Serum Rates of Cytokines: Interleukin -1 Receptor Antagonist (IL-1RA)

    Change in the serum rates of IL-1RA in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  12. Change in the Serum Rates of Cytokines: IL-6

    Change in the serum rates of IL-6 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  13. Change in the Serum Rates of Cytokines: IL-8

    Change in the serum rates of IL-8 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

  14. Change in the Serum Rates of Cytokines: Tumor Necrosis Factor (TNF-α)

    Change in the serum rates of TNF-α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

    Time frame: Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug

07

Results

Posted Jul 25, 2022

Participant flow

Enrollment was conducted at 11 clinical sites in Russian Federation. 54 subjects were screened and 47 subjects were enrolled (randomized) and treated, 44 subjects completed the study. The Safety Population and Efficacy Population included data from all 47 randomized patients to assess safety, treatment efficacy and pharmacodynamics.

Participant flow — Overall Study
MilestoneRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Started1566659
Completed1556558
Not completed010101
Withdrew: Lost to follow-up000001
Withdrew: Closure of city borders because of covid-19 quarantine010000
Withdrew: Covid-19 epidemiological situation000100

Outcome measures

PrimaryChange in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline

Change in pain intensity in the assessed joint 72 hours after the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) in comparison to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

Time frame:
Baseline and Day 4 (72 hours after the initiation of treatment with the test drug)
Reported as:
Least squares mean · mm (VAS scale)
Change in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline
mm (VAS scale)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Change in Pain Intensity in the Assessed Joint 72 Hours After the Initiation of Treatment in Comparison to Baseline-7.88 (-22.26 to 6.50)-38.56 (-60.39 to -16.72)-19.80 (-41.83 to 2.22)-33.39 (-55.53 to -11.24)-30.55 (-54.46 to -6.64)-36.51 (-55.11 to -17.90)
Statistical analysis
  • RPH - 4 mg vs Voltaren® (Diclofenac) · ANCOVA · p = 0.1331 (p-value, group) · Mean difference (final values): 28.63 · 95% CI 4.21 to 53.05Adjusted mean difference. Comparison with the control group \[RPH-104 - Diclofenac\].
  • RPH - 20 mg vs Voltaren® (Diclofenac) · ANCOVA · p = 0.1331 (p-value, group) · Mean difference (final values): -2.05 · 95% CI -30.60 to 26.50Adjusted mean difference. Comparison with the control group \[RPH-104 - Diclofenac\].
  • RPH - 40 mg vs Voltaren® (Diclofenac) · ANCOVA · p = 0.1331 (p-value, group) · Mean difference (final values): 16.70 · 95% CI -12.67 to 46.08Adjusted mean difference. Comparison with the control group \[RPH-104 - Diclofenac\].
  • RPH - 80 mg vs Voltaren® (Diclofenac) · ANCOVA · p = 0.1331 (p-value, group) · Mean difference (final values): 3.12 · 95% CI -25.10 to 31.33Adjusted mean difference. Comparison with the control group \[RPH-104 - Diclofenac\]
  • RPH - 160 mg vs Voltaren® (Diclofenac) · ANCOVA · p = 0.1331 (p-value, group) · Mean difference (final values): 5.96 · 95% CI -24.22 to 36.14Adjusted mean difference. Comparison with the control group \[RPH-104 - Diclofenac\].
SecondaryChange in Pain Intensity in the Assessed Joint in 15, 30, 45 Minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 Hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 Following the Initiation of Treatment and Compared to Baseline

Change in pain intensity in the assessed joint in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug measured using the Visual Analogue Scale (VAS) and compared to baseline. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)) The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

Time frame:
Baseline and 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment
Reported as:
Least squares mean · mm (VAS scale)
Change in Pain Intensity in the Assessed Joint in 15, 30, 45 Minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 Hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 Following the Initiation of Treatment and Compared to Baseline
mm (VAS scale)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Day 1/15 minutes-2.00 (-6.38 to 2.38)-6.97 (-13.81 to -0.14)-5.91 (-12.76 to 0.94)-1.52 (-8.39 to 5.34)-5.75 (-13.23 to 1.74)-3.78 (-9.44 to 1.88)
Day 1/30 minutes-10.00 (-16.81 to -3.19)-14.16 (-24.87 to -3.45)-6.43 (-17.15 to 4.29)-5.19 (-15.92 to 5.54)-10.57 (-22.30 to 1.16)-5.45 (-14.24 to 3.35)
Day 1/45 minutes-16.20 (-24.71 to -7.69)-16.14 (-29.55 to -2.73)-7.91 (-21.33 to 5.51)-9.36 (-22.78 to 4.07)-11.77 (-26.45 to 2.92)-8.56 (-19.55 to 2.43)
Day 1/ 1 hour-19.67 (-30.12 to -9.21)-15.81 (-32.30 to 0.69)-11.76 (-28.27 to 4.74)-12.52 (-29.03 to 3.99)-15.99 (-34.06 to 2.09)-12.67 (-26.17 to 0.83)
Day 1/ 1.5 hours-22.47 (-32.96 to -11.97)-15.14 (-31.70 to 1.42)-21.26 (-37.82 to -4.70)-14.69 (-31.26 to 1.88)-17.79 (-35.92 to 0.35)-13.67 (-27.22 to -0.12)
Day 1/ 2 hours-22.07 (-33.65 to -10.48)-25.14 (-43.42 to -6.86)-24.63 (-42.92 to -6.34)-13.86 (-32.15 to 4.44)-19.59 (-39.62 to 0.44)-20.56 (-35.52 to -5.60)
Day 1/ 4 hours-21.87 (-34.63 to -9.10)-27.27 (-47.43 to -7.12)-21.44 (-41.61 to -1.28)-14.36 (-34.52 to 5.81)-20.35 (-42.43 to 1.73)-22.67 (-39.15 to -6.19)
Day 1/ 8 hours-14.20 (-27.05 to -1.35)-29.61 (-49.89 to -9.32)-18.93 (-39.22 to 1.36)-16.52 (-36.82 to 3.77)-25.35 (-47.57 to -3.13)-25.67 (-42.26 to -9.08)
Day 2-10.60 (-23.27 to 2.07)-37.77 (-57.77 to -17.78)-20.94 (-40.95 to -0.94)-25.52 (-45.53 to -5.52)-30.35 (-52.25 to -8.44)-30.34 (-46.69 to -13.98)
Day 3-3.33 (-16.21 to 9.54)-35.77 (-56.10 to -15.45)-27.94 (-48.28 to -7.61)-34.69 (-55.03 to -14.35)-30.15 (-52.41 to -7.88)-38.67 (-55.29 to -22.05)
Day 4-6.67 (-20.38 to 7.05)-38.77 (-60.43 to -17.11)-18.91 (-40.58 to 2.76)-34.52 (-56.19 to -12.85)-30.75 (-54.47 to -7.02)-38.12 (-55.83 to -20.40)
Day 5-4.73 (-18.62 to 9.15)-31.27 (-53.20 to -9.35)-13.64 (-35.57 to 8.28)-35.86 (-57.79 to -13.92)-31.35 (-55.36 to -7.33)-42.78 (-60.71 to -24.86)
Day 6-4.80 (-18.42 to 8.82)-34.44 (-55.95 to -12.93)-12.43 (-33.95 to 9.09)-22.86 (-44.38 to -1.33)-29.15 (-52.71 to -5.58)-42.45 (-60.04 to -24.86)
Day 10-6.73 (-21.29 to 7.82)-37.27 (-60.26 to -14.29)-12.43 (-35.42 to 10.57)-23.52 (-46.52 to -0.53)-29.15 (-54.33 to -3.96)-37.78 (-56.57 to -18.99)
Day 15-4.13 (-18.21 to 9.94)-41.77 (-64.00 to -19.55)-12.41 (-34.64 to 9.82)-12.69 (-34.93 to 9.55)-28.95 (-53.30 to -4.60)-38.34 (-56.51 to -20.16)
Day 18-4.07 (-18.18 to 10.05)-42.61 (-64.90 to -20.31)-12.74 (-35.04 to 9.55)-12.69 (-34.99 to 9.61)-29.75 (-54.17 to -5.33)-28.45 (-46.67 to -10.22)
Day 22-3.20 (-17.43 to 11.03)-44.61 (-67.08 to -22.14)-13.58 (-36.05 to 8.90)-12.69 (-35.17 to 9.79)-28.35 (-52.96 to -3.73)-30.34 (-48.71 to -11.97)
Day 29-4.07 (-18.36 to 10.23)-44.94 (-67.52 to -22.36)-13.58 (-36.16 to 9.01)-12.69 (-35.28 to 9.90)-17.95 (-42.68 to 6.79)-23.89 (-42.35 to -5.43)
Day 45-2.60 (-16.67 to 11.48)-46.94 (-69.17 to -24.71)-13.58 (-35.81 to 8.66)-12.69 (-34.93 to 9.55)-19.75 (-44.09 to 4.60)-23.34 (-41.51 to -5.16)
SecondaryProportion of Patients Who Assessed the Response to Therapy With the Test Drug as "Excellent" or "Good"

Proportion of patients who assessed the response to therapy with the test drug as "Excellent" or "Good" in 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug. The patient's response to therapy was assessed in the form of frequency tables by assessment point and therapy group. The rates of the response were specified in the evaluation form as: "Excellent", "Good", "Fair", "Weak", "Poor" (where "excellent" represents the best possible response to treatment and "poor" indicates the worst treatment response).

Time frame:
15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Proportion of Patients Who Assessed the Response to Therapy With the Test Drug as "Excellent" or "Good"
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Day 1/15 minutes010101
Day 1/30 minutes210102
Day 1/45 minutes310202
Day 1/ 1 hour300201
Day 1/ 1.5 hours301101
Day 1/ 2 hours301101
Day 1/ 4 hours202112
Day 1/ 8 hours212124
Day 2102122
Day 3112125
Day 4111326
Day 5111326
Day 6121226
Day 10111226
Day 15121126
Day 18111124
Day 22021125
Day 29121113
Day 45011113
SecondaryChange in the Rate of Swelling of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

Change in the rate of swelling of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. The rates of swelling were specified in the evaluation form as: "absence" = no swelling, "mild" = palpable swelling, "moderate" = visible swelling, "severe" = bulging outside the joint (where "severe" represented the worst possible degree of swelling and "absence" was the best outcome).

Time frame:
Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Change in the Rate of Swelling of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline — absence000000
Baseline — mild100001
Baseline — moderate932415
Baseline — severe534243
Day 2/ 24 hours — absence100110
Day 2/ 24 hours — mild221115
Day 2/ 24 hours — moderate832323
Day 2/ 24 hours — severe103000
Day 3/ 48 hours — absence110312
Day 3/ 48 hours — mild131005
Day 3/ 48 hours — moderate011120
Day 3/ 48 hours — severe003000
Day 4/ 72 hours — absence121314
Day 4/ 72 hours — mild120012
Day 4/ 72 hours — moderate010011
Day 4/ 72 hours — severe002000
Day 5 — absence121314
Day 5 — mild110012
Day 5 — moderate010011
Day 5 — severe001000
Day 6 — absence121214
Day 6 — mild120023
Day 6 — moderate001000
Day 6 — severe000000
Day 10 — absence131224
Day 10 — mild100010
Day 10 — moderate001000
Day 10 — severe000000
Day 15 — absence141126
Day 15 — mild000010
Day 15 — moderate000000
Day 15 — severe000000
Day 18 — absence121122
Day 18 — mild010010
Day 18 — moderate000000
Day 18 — severe000000
22 — absence131112
22 — mild010010
22 — moderate000000
22 — severe000000
29 — absence141104
29 — mild000010
29 — moderate000000
29 — severe000000
45 — absence031104
45 — mild100010
45 — moderate000000
45 — severe000000
SecondaryChange in the Rate of Tenderness of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

Change in the rate of tenderness of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. Tenderness degrees: "absent" = no tenderness, "mild" = tenderness when touched, "moderate" = pain and flinching, "severe" = pain, flinching and withdrawal of the limb (where "severe" represents the worst possible degree of tenderness and "absent" is the best outcome).

Time frame:
Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Change in the Rate of Tenderness of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline — absence000000
Baseline — mild110000
Baseline — moderate1243426
Baseline — severe213233
Day 2/ 24 hours — absence100120
Day 2/ 24 hours — mild453116
Day 2/ 24 hours — moderate601312
Day 2/ 24 hours — severe102000
Day 3/ 48 hours — absence100111
Day 3/ 48 hours — mild152226
Day 3/ 48 hours — moderate001100
Day 3/ 48 hours — severe002000
Day 4/ 72 hours — absence120213
Day 4/ 72 hours — mild131124
Day 4/ 72 hours — moderate001000
Day 4/ 72 hours — severe001000
Day 5 — absence121313
Day 5 — mild120014
Day 5 — moderate000010
Day 5 — severe001000
Day 6 — absence121214
Day 6 — mild120023
Day 6 — moderate001000
Day 6 — severe000000
Day 10 — absence131224
Day 10 — mild100010
Day 10 — moderate001000
Day 10 — severe000000
Day 15 — absence131125
Day 15 — mild010011
Day 15 — moderate000000
Day 15 — severe000000
Day 18 — absence131121
Day 18 — mild000011
Day 18 — moderate000000
Day 18 — severe000000
22 — absence031111
22 — mild110011
22 — moderate000000
22 — severe000000
29 — absence131113
29 — mild010001
29 — moderate000000
29 — severe000000
45 — absence031104
45 — mild100010
45 — moderate000000
45 — severe000000
SecondaryChange in the Rate of Erythema of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug

Change in the rate of erythema of the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline.The rates of "erythema" were specified as "absence", "presence", "impossible to evaluate".

Time frame:
Baseline and 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Change in the Rate of Erythema of the Assessed Joint Evaluated After the Initiation of Treatment With the Test Drug
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline — absence300002
Baseline — presence1266557
Baseline — evaluation impossible000100
Day 2/ 24 hours — absence521122
Day 2/ 24 hours — presence734426
Day 2/ 24 hours — evaluation impossible001000
Day 3/ 48 hours — absence242315
Day 3/ 48 hours — presence012122
Day 3/ 48 hours — evaluation impossible001000
Day 4/ 72 hours — absence241327
Day 4/ 72 hours — presence012010
Day 4/ 72 hours — evaluation impossible000000
Day 5 — absence241337
Day 5 — presence001000
Day 5 — evaluation impossible000000
Day 6 — absence241237
Day 6 — presence001000
Day 6 — evaluation impossible000000
Day 10 — absence231234
Day 10 — presence001000
Day 10 — evaluation impossible000000
Day 15 — absence141136
Day 15 — presence000000
Day 15 — evaluation impossible000000
Day 18 — absence131132
Day 18 — presence000000
Day 18 — evaluation impossible000000
22 — absence141122
22 — presence000000
22 — evaluation impossible000000
29 — absence131114
29 — presence010000
29 — evaluation impossible000000
45 — absence131114
45 — presence000000
45 — evaluation impossible000000
SecondaryChange in the Rate of Movement Restrictions in the Specified Timeframes After Initiation of Treatment

Change in the rate of movement restrictions in the assessed joint evaluated in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug compared to baseline. For the assessment, the categorical scale consistent with the Form for evaluation (Investigator's Assessment) of the restriction of movements was used. The rates of movement restrictions (amplitude of movements) were specified in the evaluation form as "1 - Normal range", "2 - Slightly limited range", " 3 - Moderately limited range" ,"4 - Severely limited range" and "5 - Joint movement is impossible " (where higher score means worse outcome).

Time frame:
Baseline and in 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Change in the Rate of Movement Restrictions in the Specified Timeframes After Initiation of Treatment
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline — 1000000
Baseline — 2000000
Baseline — 3521326
Baseline — 4945223
Baseline — 5100110
Day 2/ 24 hours — 1100000
Day 2/ 24 hours — 2010224
Day 2/ 24 hours — 3733213
Day 2/ 24 hours — 4312111
Day 2/ 24 hours — 5101000
Day 3/ 48 hours — 1000111
Day 3/ 48 hours — 2152214
Day 3/ 48 hours — 3101102
Day 3/ 48 hours — 4001010
Day 3/ 48 hours — 5001000
Day 4/ 72 hours — 1121212
Day 4/ 72 hours — 2030115
Day 4/ 72 hours — 3101000
Day 4/ 72 hours — 4001010
Day 4/ 72 hours — 5000000
Day 5 — 1131313
Day 5 — 2010014
Day 5 — 3100000
Day 5 — 4001010
Day 5 — 5000000
Day 6 — 1131215
Day 6 — 2010012
Day 6 — 3100000
Day 6 — 4001010
Day 6 — 5000000
Day 10 — 1131223
Day 10 — 2000001
Day 10 — 3100000
Day 10 — 4001010
Day 10 — 5000000
Day 15 — 1131125
Day 15 — 2010001
Day 15 — 3000010
Day 15 — 4000000
Day 15 — 5000000
Day 18 — 1031122
Day 18 — 2100000
Day 18 — 3000010
Day 18 — 4000000
Day 18 — 5000000
Day 22 — 1031112
Day 22 — 2110000
Day 22 — 3000010
Day 22 — 4000000
Day 22 — 5000000
Day 29 — 1031104
Day 29 — 2100000
Day 29 — 3010010
Day 29 — 4000000
Day 29 — 5000000
Day 45 — 1031104
Day 45 — 2000000
Day 45 — 3100010
Day 45 — 4000000
Day 45 — 5000000
SecondaryTime to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the Baseline

Time to achieve the 50% decrease in pain intensity in the assessed joint relative to the baseline VAS level. VAS is a hard copy 100 mm scale with the indications: "Absence of pain" on the left side of the scale (0 mm point) and "The most severe pain ever experienced" on the right side of the scale (100 mm point)). The better outcome would be "Absence of pain", the worse outcome would be "The most severe pain ever experienced".

Time frame:
Baseline and one of the pain intensity measurements in accordance with the schedule: 15, 30, 45 minutes, 1, 1.5, 2, 4, 8, 24, 48, 72 hours, on Days 5, 6, 10, 15, 18, 22, 29 and 45 after the initiation of treatment
Reported as:
Median · hours
Time to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the Baseline
hoursRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Time to Achieve the 50% Decrease in Pain Intensity in the Assessed Joint Relative to the BaselineNA (0.8 to NA)6.0 (0.3 to NA)NA (1.5 to NA)NA (0.8 to NA)8.0 (4.0 to NA)47.3 (0.8 to NA)
Statistical analysis
  • RPH - 20 mg vs Voltaren® (Diclofenac) · Log Rank · p = 0.5995
  • RPH - 160 mg vs Voltaren® (Diclofenac) · Log Rank · p = 0.9012
SecondaryTime to Use of the Rescue Medication

Time to use of the rescue medication was calculated as the time in hours from the date/time of administration (first dose) of the investigational product to the date/time of the first use of the rescue medication.

Time frame:
from the date/time of IP administration (first dose) to the date/time of the first use of the rescue medication, up to day 60
Reported as:
Median · hours
Time to Use of the Rescue Medication
hoursRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Time to Use of the Rescue Medication23.7 (21.3 to 24.5)NA (3.1 to NA)71.8 (24.4 to NA)84.6 (22.7 to NA)NA (3.0 to NA)NA (4.4 to NA)
SecondaryProportion of Patients Who Received a Rescue Therapy Agent

The proportion of patients who received the rescue medication within 72 hours of starting the investigational product therapy

Time frame:
72 hours after the initiation of treatment with the test drug
Reported as:
Count of participants · Participants
Proportion of Patients Who Received a Rescue Therapy Agent
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Proportion of Patients Who Received a Rescue Therapy Agent1213322
Statistical analysis
  • RPH - 4 mg vs Voltaren® (Diclofenac) · Fisher Exact · p = 0.0066 · Difference in proportions: 63.5 · 95% CI 19.9 to 88.6
  • RPH - 20 mg vs Voltaren® (Diclofenac) · Fisher Exact · p = >0.9999 · Difference in proportions: -5.6 · 95% CI -50.1 to 45.5
  • RPH - 40 mg vs Voltaren® (Diclofenac) · Fisher Exact · p = 0.3287 · Difference in proportions: 27.8 · 95% CI -26.8 to 71.8
  • RPH - 80 mg vs Voltaren® (Diclofenac) · Fisher Exact · p = 0.3287 · Difference in proportions: 27.8 · 95% CI -26.8 to 71.8
  • RPH - 160 mg vs Voltaren® (Diclofenac) · Fisher Exact · p = 0.5804 · Difference in proportions: 17.8 · 95% CI -33.7 to 67.8
SecondaryProportion of Patients Who Received a Rescue Therapy Agent

The proportion of patients who received the rescue medication over the entire treatment period

Time frame:
up to day 60
Reported as:
Count of participants · Participants
Proportion of Patients Who Received a Rescue Therapy Agent
ParticipantsRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Proportion of Patients Who Received a Rescue Therapy Agent1314423
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Disability Index

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. (The result for each of the 8 categories ("Dressing and Grooming", "Arising", "Eating", "Walking", "Hygiene", "Reach", "Grip", "Activities") of the HAQ questionnaire was calculated as the maximum score of responses (on an ordinal scale from 0 (best) to 3 (worst): without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3)) to questions included in this category. If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2". The sum of points for the evaluated categories was calculated and divided by the number of categories, which gives a disability index in the range of 0 to 3.)

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Disability Index
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.3 ± 0.8021.23 ± 0.5781.75 ± 0.8061.1 ± 0.6491.6 ± 0.6151.32 ± 0.577
Change Day 15-0.75 ± NA-0.63 ± 0.685-0.88 ± NA-0.63 ± NA-1.06 ± 0.619-0.56 ± 0.342
Change Day 29-0.13 ± NA-1.09 ± 0.672-1.25 ± NA-0.63 ± NA-0.5 ± 0.53-0.38 ± 0.144
Change Day 45-0.38 ± NA-1.42 ± 0.382-1.38 ± NA-0.63 ± NA-0.56 ± 0.619-0.44 ± 0.298
Other pre-specifiedPharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration

Including area under the plasma concentration-time curve over the dosing interval (AUC0-tau)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Geometric mean · h*ng/mL
Pharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration
h*ng/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) - Area Under the Plasma concentration-of RPH-104 Under the Subcutaneous Administration38000 ± 124762000 ± 152845000 ± 451620000 ± 36.53230000 ± 38.2
Other pre-specifiedPharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration

Including Area under the active substance concentration-time curve from zero (before drug administration) to infinity (AUC0-∞)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Geometric mean · h*ng/mL
Pharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration
h*ng/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) - Area Under the Active Substance Concentration- of RPH-104 Under the Subcutaneous Administration47900 ± 97.9816000 ± 155901000 ± 44.31720000 ± 37.13380000 ± 38.1
Other pre-specifiedPharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration

Including Maximum concentration of the active substance (Cmax)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration
ng/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) - Maximum Concentration of the Active Substance -of RPH-104 Under the Subcutaneous Administration142 ± 1102220 ± 1552380 ± 47.74860 ± 189760 ± 38.2
Other pre-specifiedPharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration

Including elimination constant (Kel)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Mean · 1/h
Pharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration
1/hRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) of RPH-104 Under the Subcutaneous Administration0.00298 ± 0.0005730.00314 ± 0.0006220.00304 ± 0.0002410.00317 ± 0.0005750.00294 ± 0.000311
Other pre-specifiedPharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration

Including Time to reach maximum concentration of the active substance (tmax)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Median · hours
Pharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration
hoursRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) -Time to Reach Maximum Concentration of the Active Substance - of RPH-104 Under the Subcutaneous Administration93.7 (8 to 120)47.5 (21.3 to 72.1)84.8 (47.1 to 120)82.7 (24 to 122)94.4 (72 to 96.1)
Other pre-specifiedPharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration

Including terminal half-life (T 1/2)

Time frame:
Baseline and in 2,8,24,48,72 hours,on Days 5,6,10,15,18,22,29,45 following the initiation of treatment with the test drug and on the follow-up visit (in case of premature withdrawal of patient)
Reported as:
Median · hours
Pharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration
hoursRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mg
Pharmacokinetics (PK) - Terminal Half-life -of RPH-104 Under the Subcutaneous Administration248 (153 to 285)235 (170 to 274)223 (205 to 256)231 (168 to 264)241 (212 to 261)
Other pre-specifiedChange in the Serum Rate of High-sensitive CRP (Hs-CRP) in Specified Timeframes

Change in the serum rate of high-sensitive CRP (hs-CRP) in 24, 72 hours, on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug compared to baseline

Time frame:
Baseline and in 24, 72 hours, on Days 5, 6, 15, 29 and 45 after the initiation of treatment with the test drug
Reported as:
Mean · mg/L
Change in the Serum Rate of High-sensitive CRP (Hs-CRP) in Specified Timeframes
mg/LRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value36.673 ± 31.35458.295 ± 6.621210.105 ± 14.283437.908 ± 25.559435.396 ± 32.480015.769 ± 18.0878
Day 2/ 24 hours35.468 ± 32.202520.338 ± 33.372824.483 ± 16.354328.864 ± 16.119412.000 ± 11.551822.716 ± 26.9958
Day 4/ 72 hours33.894 ± 35.08733.408 ± 0.812012.900 ± 9.357911.846 ± 6.17808.678 ± 10.50379.279 ± 8.1642
Day 532.279 ± 32.68583.090 ± 0.90767.142 ± 5.70718.696 ± 3.64686.178 ± 6.42628.877 ± 6.3308
Day 629.065 ± 28.12882.710 ± 1.61403.650 ± 2.84454.604 ± 1.38713.190 ± 3.01658.417 ± 7.0440
Day 1521.017 ± 28.43842.642 ± 1.43223.304 ± 5.80185.115 ± 3.53824.042 ± 6.11996.579 ± 4.4134
Day 2916.811 ± 26.39227.532 ± 13.06152.750 ± 2.90685.014 ± 2.848010.998 ± 17.34637.595 ± 7.9870
Day 4524.958 ± 29.44503.570 ± 2.19072.445 ± 1.83153.093 ± 0.565214.500 ± 19.288211.734 ± 11.4627
Other pre-specifiedChange in the Rate of Serum Amyloid Protein A in the Specified Timeframes

Change in the rate of serum amyloid protein A in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Day 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · ng/mL
Change in the Rate of Serum Amyloid Protein A in the Specified Timeframes
ng/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value13493.687 ± 14565.04492516.606 ± 1367.798116764.020 ± 14525.107216168.130 ± 12937.737716291.605 ± 17949.67415033.151 ± 3384.3761
Day 2/ 24 hours17424.060 ± 17167.207311078.300 ± 19281.382220104.555 ± 15608.376015581.486 ± 13271.71153659.778 ± 3244.20997294.631 ± 5163.5001
Day 4/ 72 hours17588.735 ± 16623.43011171.203 ± 400.385112162.612 ± 12060.275314419.760 ± 11828.254610596.423 ± 16813.32537362.322 ± 9834.7459
Day 517360.201 ± 15874.52371195.975 ± 393.69815680.190 ± 5708.90228228.272 ± 7624.13295952.460 ± 10455.68568252.633 ± 8121.6203
Day 618553.955 ± 15454.23731847.923 ± 1646.01254781.173 ± 6120.57285799.608 ± 5562.99806117.777 ± 8569.97566165.779 ± 5356.4841
Day 159272.782 ± 11297.96761525.612 ± 502.88458899.982 ± 17399.00424582.338 ± 5995.59932732.598 ± 1325.36986031.146 ± 10261.9489
Day 298918.439 ± 12001.14924255.756 ± 6845.19471645.107 ± 1044.88113626.702 ± 2740.12833618.843 ± 3147.23193779.410 ± 2727.9500
Day 4513858.845 ± 16512.55752086.198 ± 2799.50391269.680 ± 695.35111567.040 ± 1421.45419885.230 ± 15228.96077289.553 ± 7189.8429
Other pre-specifiedChange in the Serum Rates of Cytokines: IL-1α

Change in the serum rates of IL-1α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: IL-1α
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.752 ± 1.53901.090 ± 0.00001.090 ± 0.0000
Day 2/ 24 hours1.090 ± 0.00001.090 ± 0.00001.097 ± 0.01631.782 ± 1.54741.090 ± 0.00001.090 ± 0.0000
Day 4/ 72 hours1.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.688 ± 1.33721.090 ± 0.00001.090 ± 0.0000
Day 51.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.790 ± 1.56521.090 ± 0.00001.090 ± 0.0000
Day 61.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.612 ± 1.16721.090 ± 0.00001.090 ± 0.0000
Day 151.132 ± 0.15251.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.0000
Day 291.097 ± 0.02581.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.0000
Day 451.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.00001.090 ± 0.0000
Other pre-specifiedChange in the Serum Rates of Cytokines: IL-1β

Change in the serum rates of IL-1β in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: IL-1β
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value39.035 ± 138.50781.080 ± 1.93510.290 ± 0.00002.558 ± 3.52480.290 ± 0.00000.290 ± 0.0000
Day 2/ 24 hours33.885 ± 128.95190.290 ± 0.00000.290 ± 0.00001.100 ± 1.81120.290 ± 0.00000.290 ± 0.0000
Day 4/ 72 hours33.759 ± 128.98590.290 ± 0.00000.290 ± 0.00002.112 ± 4.07410.290 ± 0.00000.290 ± 0.0000
Day 533.753 ± 128.98730.290 ± 0.00000.290 ± 0.00000.290 ± 0.00000.290 ± 0.00000.290 ± 0.0000
Day 633.998 ± 128.92310.290 ± 0.00000.290 ± 0.00002.362 ± 4.63310.290 ± 0.00000.290 ± 0.0000
Day 1538.730 ± 138.59741.222 ± 2.08400.290 ± 0.00001.965 ± 3.35000.290 ± 0.00000.290 ± 0.0000
Day 2933.811 ± 128.97241.320 ± 2.30320.417 ± 0.31031.746 ± 3.25570.290 ± 0.00000.290 ± 0.0000
Day 450.290 ± 0.00000.290 ± 0.00000.290 ± 0.00000.290 ± 0.00000.290 ± 0.00000.290 ± 0.0000
Other pre-specifiedChange in the Serum Rates of Cytokines: Interleukin -1 Receptor Antagonist (IL-1RA)

Change in the serum rates of IL-1RA in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: Interleukin -1 Receptor Antagonist (IL-1RA)
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value2400.500 ± 1495.11001448.978 ± 527.86581671.010 ± 1225.26732240.155 ± 937.19882619.456 ± 2706.33972090.721 ± 1240.5717
Day 2/ 24 hours1700.180 ± 1448.4981229.842 ± 291.9887153.098 ± 145.378029.990 ± 0.000029.990 ± 0.00002483.891 ± 1786.0361
Day 4/ 72 hours1295.743 ± 916.8659156.216 ± 110.6281140.108 ± 123.8956157.654 ± 227.233429.990 ± 0.00002297.651 ± 1361.7429
Day 51364.993 ± 1106.8245187.223 ± 109.9846154.463 ± 124.669087.214 ± 79.726929.990 ± 0.00002417.991 ± 1416.8428
Day 61407.230 ± 927.8243214.610 ± 125.9518203.688 ± 133.0562180.492 ± 112.266429.990 ± 0.00002426.761 ± 1452.6687
Day 151620.332 ± 935.4363374.900 ± 96.9459474.542 ± 214.5880645.085 ± 300.6542257.492 ± 166.07382249.794 ± 1459.3243
Day 291928.417 ± 1048.0875563.892 ± 142.6097583.062 ± 269.1237686.992 ± 305.9470471.178 ± 267.82621870.815 ± 1032.8765
Day 451806.647 ± 858.8185915.010 ± 177.2813808.212 ± 354.6509711.997 ± 285.9941518.063 ± 201.14551969.547 ± 1352.6193
Other pre-specifiedChange in the Serum Rates of Cytokines: IL-6

Change in the serum rates of IL-6 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: IL-6
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value26.035 ± 39.12575.005 ± 4.602234.307 ± 54.32645.623 ± 6.856413.666 ± 11.96956.058 ± 6.9686
Day 2/ 24 hours27.030 ± 42.99082.084 ± 1.893037.788 ± 72.31876.284 ± 11.11539.065 ± 12.58432.361 ± 1.2039
Day 4/ 72 hours14.943 ± 29.90082.236 ± 1.85332.145 ± 0.99613.142 ± 3.72904.698 ± 7.32231.702 ± 1.1067
Day 523.999 ± 37.56782.695 ± 2.29492.378 ± 1.94321.396 ± 0.50314.905 ± 7.51141.823 ± 1.6473
Day 68.391 ± 13.37423.565 ± 3.52822.965 ± 3.49911.272 ± 0.36366.220 ± 9.84912.157 ± 2.1250
Day 1510.595 ± 14.44442.870 ± 1.58382.434 ± 1.79291.793 ± 0.590712.858 ± 25.31492.036 ± 1.2089
Day 2918.643 ± 50.46582.758 ± 1.73153.278 ± 4.22451.482 ± 0.533417.903 ± 31.13355.304 ± 7.4387
Day 456.466 ± 9.12614.608 ± 5.89993.370 ± 4.50511.537 ± 0.39113.753 ± 1.60942.607 ± 1.9663
Other pre-specifiedChange in the Serum Rates of Cytokines: IL-8

Change in the serum rates of IL-8 in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: IL-8
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value12.384 ± 5.829721.964 ± 24.87599.277 ± 4.534718.305 ± 21.892112.318 ± 12.570210.863 ± 7.1505
Day 2/ 24 hours8.228 ± 7.12179.304 ± 9.76099.030 ± 5.501412.304 ± 9.91362.668 ± 1.355017.141 ± 13.6494
Day 4/ 72 hours15.601 ± 19.47148.708 ± 5.89519.020 ± 6.20305.952 ± 4.49918.148 ± 5.602515.980 ± 11.7350
Day 513.521 ± 7.89884.313 ± 2.69418.032 ± 4.940210.518 ± 6.809811.190 ± 4.437615.188 ± 12.3696
Day 616.969 ± 16.97238.015 ± 4.68977.937 ± 5.31997.594 ± 5.944910.745 ± 6.301019.881 ± 21.0673
Day 159.765 ± 9.353620.884 ± 31.650711.520 ± 7.431316.395 ± 19.55563.060 ± 2.392634.770 ± 66.4033
Day 2919.766 ± 20.887925.622 ± 36.47438.003 ± 6.13688.596 ± 9.21149.243 ± 5.14418.554 ± 7.6207
Day 4512.664 ± 7.24675.468 ± 4.11205.807 ± 5.82727.223 ± 3.08917.927 ± 5.305111.763 ± 11.1239
Other pre-specifiedChange in the Serum Rates of Cytokines: Tumor Necrosis Factor (TNF-α)

Change in the serum rates of TNF-α in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug as compared to baseline

Time frame:
Baseline and in 24, 72 hours and on Days 5, 6, 15, 29 and 45 following the initiation of treatment with the test drug
Reported as:
Mean · pg/mL
Change in the Serum Rates of Cytokines: Tumor Necrosis Factor (TNF-α)
pg/mLRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value2.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 2/ 24 hours2.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 4/ 72 hours2.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 52.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 62.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 152.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 292.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
Day 452.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.00002.290 ± 0.0000
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Arising

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Arising
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value0.9 ± 0.741.3 ± 0.521.5 ± 1.050.7 ± 0.821.4 ± 0.551.2 ± 0.97
Change Day 15-1.0 ± NA-1.0 ± 0.82-1.0 ± NA0.0 ± NA-1.0 ± 0.00-0.5 ± 0.55
Change Day 29-1.0 ± NA-1.3 ± 0.50-1.0 ± NA0.0 ± NA-0.5 ± 0.710.0 ± 0.82
Change Day 45-1.0 ± NA-1.3 ± 0.58-1.0 ± NA0.0 ± NA-0.5 ± 0.710.0 ± 0.0
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Eating

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Eating
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.0 ± 1.200.7 ± 0.821.3 ± 1.370.8 ± 1.171.0 ± 1.000.7 ± 1.00
Change Day 150.0 ± NA-0.5 ± 1.00.0 ± NA0.0 ± NA0.0 ± 0.00-0.3 ± 0.52
Change Day 290.0 ± NA-1.0 ± 0.820.0 ± NA0.0 ± NA-0.5 ± 0.71-0.3 ± 0.50
Change Day 450.0 ± NA-1.3 ± 0.580.0 ± NA0.0 ± NA-0.5 ± 0.71-0.3 ± 0.5
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Walking

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Walking
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.4 ± 0.741.8 ± 0.751.8 ± 1.171.3 ± 0.821.6 ± 1.141.8 ± 0.67
Change Day 150.0 ± NA-1.3 ± 0.96-1.0 ± NA-1.0 ± NA-1.5 ± 0.71-0.7 ± 0.82
Change Day 290.0 ± NA-1.3 ± 0.96-2.0 ± NA-1.0 ± NA-0.5 ± 0.71-0.3 ± 0.50
Change Day 450.0 ± NA-1.3 ± 1.15-2.0 ± NA-1.0 ± NA-0.5 ± 0.71-0.8 ± 0.96
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Hygiene

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Hygiene
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.2 ± 1.211.2 ± 0.981.7 ± 1.031.5 ± 1.052.2 ± 0.451.3 ± 0.50
Change Day 15-1.0 ± NA-0.3 ± 1.26-1.0 ± NA-1.0 ± NA-2.5 ± 0.71-0.5 ± 0.55
Change Day 291.0 ± NA-1.3 ± 0.96-1.0 ± NA-1.0 ± NA-0.5 ± 0.71-0.5 ± 0.58
Change Day 450.0 ± NA-1.7 ± 0.58-1.0 ± NA-1.0 ± NA-0.5 ± 0.71-1.0 ± 0.82
SecondaryChanges in the Health Assessment Questionnaire (HAQ) Parameters: Grip

Changes in the Health Assessment Questionnaire (HAQ) parameters in 15, 29 and 45 days following the initiation of treatment with the test drug as compared to baseline. The result was calculated as the maximum score of responses (on an ordinal scale from 0 to 3) to questions included in this category. Patients were asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst). If the patient required outside help or any of the specified aids or devices to perform actions related to a certain category, then this category was assigned "2" points, if the point was not equal to "3", i.e. points "0" and "1" increased to "2".

Time frame:
Baseline and 15, 29 and 45 days following the initiation of treatment with the test drug
Reported as:
Mean · units of the HAQ index
Changes in the Health Assessment Questionnaire (HAQ) Parameters: Grip
units of the HAQ indexRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Baseline value1.4 ± 0.991.0 ± 0.631.2 ± 1.171.0 ± 1.101.2 ± 1.100.4 ± 0.73
Change Day 15-1.0 ± NA-0.5 ± 0.580.0 ± NA-1.0 ± NA0.0 ± 0.00-0.2 ± 0.41
Change Day 29-1.0 ± NA-1.0 ± 0.820.0 ± NA-1.0 ± NA-0.5 ± 0.71-0.3 ± 0.5
Change Day 45-1.0 ± NA-1.3 ± 0.580.0 ± NA-1.0 ± NA-1.0 ± 1.410.3 ± 1.26

Adverse events

Collected over The safety of the investigational product was assessed over a 60-day period of therapy and follow-up. The tables show AEs that developed from the start of therapy.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RPH - 4 mg0/15 (0%)0/15 (0%)11/15 (73.3%)
RPH - 20 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
RPH - 40 mg0/6 (0%)0/6 (0%)3/6 (50%)
RPH - 80 mg0/6 (0%)2/6 (33.3%)3/6 (50%)
RPH - 160 mg0/5 (0%)0/5 (0%)4/5 (80%)
Voltaren® (Diclofenac)0/9 (0%)1/9 (11.1%)2/9 (22.2%)
Most frequent serious events
Most frequent serious events
EventRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
drug-induced liver injuryHepatobiliary disorders0/150/60/61/60/50/9
Mycobacterium tuberculosis complex test positiveInvestigations0/150/60/61/60/50/9
pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/150/60/61/60/50/9
CellulitisInfections and infestations0/150/60/60/60/51/9
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)
Cholecystitis chronicHepatobiliary disorders0/150/60/62/60/50/9
Gouty arthritisMusculoskeletal and connective tissue disorders5/151/61/61/61/50/9
LeukocytosisBlood and lymphatic system disorders0/151/60/60/61/50/9
Sinus tachycardiaCardiac disorders0/150/60/60/61/50/9
AstheniaGeneral disorders0/150/60/60/61/50/9
Injection site erythemaGeneral disorders0/150/60/60/61/50/9
Injection site pruritusGeneral disorders0/150/60/60/61/50/9
Blood cholesterol increasedInvestigations0/150/60/60/61/50/9
Blood creatinine increasedInvestigations1/150/61/60/61/51/9
Blood triglycerides increasedInvestigations0/150/61/60/61/50/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)Total
Mean52.3 (31 to 63)51.7 (46 to 60)42.8 (34 to 57)56.5 (41 to 78)53.6 (50 to 59)52.2 (42 to 61)51.5 (31 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)Total
Female0100023
Male155665744
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)Total
Race — Caucasian/White156665947
Race — other0000000
Disease duration
Disease duration(years)RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)Total
Mean8.13 (0.9 to 17.2)7.65 (0.1 to 17.3)8.04 (2.4 to 19.4)9.16 (0.9 to 15.9)13.55 (7.4 to 29.3)6.41 (0.1 to 12.5)8.82 (0.1 to 29.3)
Exact number of affected joints
Exact number of affected joints(number (of joints))RPH - 4 mgRPH - 20 mgRPH - 40 mgRPH - 80 mgRPH - 160 mgVoltaren® (Diclofenac)Total
Mean5.3 (1 to 23)3.0 (1 to 5)5.7 (1 to 25)2.7 (1 to 5)6.2 (2 to 16)3.0 (1 to 7)4.32 (1 to 25)
08

Study locations

11 sites
  • Moscow City State Healthcare Institution "O.M. Filatov Municipal Clinical Hospital No. 15" of the Moscow Department of Healthcare
    Moscow, 111539, Russian Federation
  • State Budgetary Healthcare Institution of Moscow City "Municipal Clinical Hospital No.1 named after N.I. Pirogov" of Moscow Department of Healthcare
    Moscow, 119049, Russian Federation
  • Federal State Autonomous Educational Institution of Higher Education "I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
    Moscow, 119991, Russian Federation
  • State Budgetary Healthcare Institution of Moscow City "Municipal Clinical Hospital No.52" of Moscow Department of Healthcare
    Moscow, 123182, Russian Federation
  • State Budgetary Institution of Healthcare of Nizhny Novgorod region "City Clinical hospital #13 of Avozavodskiy district"
    Nizhny Novgorod, 603018, Russian Federation
  • Federal State Budgetary Education Institution of Higher Education "Orenburg State Medical University" under Ministry of Healthcare of Russian Federation
    Orenburg, 460000, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "Clinical Rheumatological Hospital No.25"
    Saint Petersburg, 190068, Russian Federation
  • State Budget Institution "Saint Petersburg Research Insitute of emergency care named after I.I. Dzhanelidze
    Saint Petersburg, 192242, Russian Federation
  • Limited Liability company "Scientific Research Center Eco-safety"
    Saint Petersburg, 196143, Russian Federation
  • State Insitution of healthcare "Tula regional clinical dermatovenerologic dispensary"
    Tula, 300053, Russian Federation
  • State Autonomous Healthcare Institution of the Yaroslavl Region "N.V. Solovyev Clinical Emergency Hospital"
    Yaroslavl, 150003, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Mar 2020, 23 months.

Results were first posted in Jul 2022, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2019
First posted
Aug 26, 2019
StartActual
Mar 26, 2018
Primary completionActual
Mar 16, 2020
CompletionActual
May 12, 2020
Results first posted
Jul 25, 2022
Last update
Jul 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04067492
Lead sponsor
R-Pharm
Collaborators
Covance, Unimed Laboratories, Data Matrix Solutions, Center of Pharmaceutical Analytics LLC, OCT LLC
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Mar 26, 2018
Primary completion
Mar 16, 2020
Completion
May 12, 2020
Results posted
Jul 25, 2022
Last update
Jul 25, 2022

Study contacts

Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goflikicept

Start the discussion